Expression of FGFR3 Protein and Gene Amplification in Urinary Bladder Lesions in Relation to Schistosomiasis
DOI:
https://doi.org/10.3889/oamjms.2017.048Keywords:
FGFR3, IHC, FISH, urothelial bladder lesions, cystitis, carcinomaAbstract
BACKGROUND: Bladder cancer represents the fifth most common malignancy worldwide and a major cause of cancer-related morbidity and death. Incidence and mortality rates have remained relatively constant over the past four decades. Urothelial bladder cancers have identified multiple risk factors.
AIM: We aimed at evaluating the expression of the FGFR3 protein and gene amplification in the urothelial cells of neoplastic and non-neoplastic urothelial lesions of the urinary bladder, and correlation with tumour grade, stage and associated bilharziasis.
MATERIAL AND METHODS: One hundred and five different urinary bladder lesions were studied, including 15 cystitis cases (9 bilharzial and 6 non-bilharzial cystitides), 75 urothelial carcinoma cases (18 bilharzial associated and 57 non-bilharzial associated) and 15 squamous cell carcinoma associated with bilharziasis, beside 5 control cases. Data concerning age, sex, tumour grade, stage, and associated bilharziasis were obtained. Each case was studied for FGFR3 expression, and FISH technique was applied on forty malignant cases that show high protein expression.
RESULTS: The highest incidence of cystitis was in the fourth decade while of bladder cancer was in the seventh decade. Tumour grade was correlated significantly with tumour stage. FGFR3 correlates significantly with tumour grade, stage and with a bilharzial infestation. FGFR3 gene amplification was reported mainly in low grade and NNMBIC tumours.
CONCLUSIONS: FGFR3 overexpression in malignant cases was significantly higher than in chronic cystitis. FGFR3 gene amplification was reported mainly in low grade and NNMBIC tumours. FGFR3 may be further studied as a subject for target therapy of bladder cancer.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ashley SF, Soliman SA, Khaled H, Zaghloul SM, Mousumi B. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer causes Control. 2008; 19: 421. https://doi.org/10.1007/s10552-007-9104-7 PMid:18188671 PMCid:PMC4274945
Rambau PF, Chalya PL, Jackson k. Schistosomiasis and urinary bladder cancer in North Western Tanzania: a retrospective review of 185 patients. Infectious Agents and Cancer. 2013; 8:19. https://doi.org/10.1186/1750-9378-8-19 PMid:23705833 PMCid:PMC3665673
Michaud DS, Clinton SK,Rimm EB. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology. 2001; 12:719. https://doi.org/10.1097/00001648-200111000-00022 PMid:11679802
Pritchett TR, Wang JK, and Jones PA. Mesenchymal-epithelial interactions between normal and transformed human bladder cancer cells. Cancer Res.1989; 49: 2750. PMid:2713858
di Martino E, Tomlinson DC, Knowles MA. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges Advances in Urology. 2012 (2012), Article ID 429213.
van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012; 187(1):310-4. PMid:22099989
Foth M, Ahmad I , van Rhijn BWG, van der Kwast T, Andre M. Bergman AM, King L, Ridgway R, Leung HY, Fraser S, Sansom OG, Iwata T. Fibroblast Growth Factor Receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J Pathol. 2014 ; 233(2): 148–158. https://doi.org/10.1002/path.4334 PMid:24519156 PMCid:PMC4612374
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RG, Hirsch MS, Justine A Barletta JA, Berman DM, Lis R, Loda M, Stack EC,8 Levi A Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014; 3(4): 835–844. https://doi.org/10.1002/cam4.262 PMid:24846059 PMCid:PMC4303151
Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007; 213(1):91-8. https://doi.org/10.1002/path.2207 PMid:17668422 PMCid:PMC2443273
Lievens PM, Zanolli E, Garofalo S, Liboi E. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum. FEBS Lett. 2009;583(19):3254-8. https://doi.org/10.1016/j.febslet.2009.09.021 PMid:19761767
van Rhijn, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff CE. The Fibroblast Growth Factor Receptor 3 (FGFR3) Mutation Is a Strong Indicator of Superficial Bladder Cancer with Low Recurrence Rate. Cancer Res. 2001;61:1265-1268. PMid:11245416
Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumors of the urinary system and male genital organs. World Health Organization Classification of Tumors. Lyon, France: IARC Press, 2004. PMCid:PMC1618623
AJCC CANCER STAGING MANUAL Seventh Edition American Joint Committee on Cancer Executive Office, 633 North Saint Clair Street Chicago, IL 60611-3211, 2010:503-504.
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013; 57(4):1407-15. https://doi.org/10.1002/hep.25956 PMid:22890726
Khaled H. "Schistosomiasis and Cancer in Egypt: Review". Journal of Advanced Research. 2013; 4(5):461-466. https://doi.org/10.1016/j.jare.2013.06.007 PMid:25685453 PMCid:PMC4293882
Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. 2009; 28(1): 27. https://doi.org/10.1186/1756-9966-28-27 PMid:19243595 PMCid:PMC2650688
Salim EI, Morimura K, Menesi A, El-Lity M, Fukushima S, Wanibuchi H. Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis. International Journal of Cancer. 2008; 123(3). https://doi.org/10.1002/ijc.23547 PMid:18478569
Gust KM , McConkey DJ , Awrey S , Hegarty PK , Qing J , BondarukJ , Ashkenazi A , Czerniak B , DinneyCP , BlackPC. Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer Mol Cancer Ther. 2013; 12(7).
Junker K, van Oers GMM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast Growth Factor Receptor 3 Mutations in Bladder Tumors Correlate with Low Frequency of Chromosome Alterations. Neoplasia. 2008; 10(1): 1–7. https://doi.org/10.1593/neo.07178 PMid:18231634 PMCid:PMC2213896
Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns1,Doris Mannhard T, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. J Clin Pathol 2015; 2015-202898.
Bodoor K, Ghabkari A, Jaradat Z et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010; 34; 724–732. https://doi.org/10.1016/j.canep.2010.05.003 PMid:20542753
Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom R, Heidenreich A, Schneevoigt BS, Hauke S, Hartmann A, Knuechel R, Veeck J, Gaisa NT. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology. 2015;66(5):639-49. https://doi.org/10.1111/his.12473 PMid:24898159
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
